Zai Lab partner Novocure's LUNAR Phase 3 trial meets endpoint, shows 3-month OS improvement in metastatic NSCLC

Zai Lab Ltd

TTFields + standard therapies improved median OS from 9.9 to 13.2 months (HR 0.74, p=0.035) in post-platinum metastatic NSCLC.
ICI subgroup median OS was 18.5 vs 10.8 months (HR 0.63, p=0.03), an 8-month improvement.
TTFields was well-tolerated with no added systemic toxicities; only grade 3 device-related AEs.
Novocure plans PMA submission to FDA in H2 2023; Zai Lab will file MAA to China's NMPA thereafter.
Zai Lab has exclusive license to develop/commercialize TTFields in Greater China.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.